TICKERNERD
Menu
FTHHealthcare · Biotechnology

FTH Stock Forecast: Faeth Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$20
+1.73% on the day

The 15 Wall Street analysts covering Faeth Therapeutics, Inc. hold a median 12-month price target of $56 — +180.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 4 Nov 2026 — in the lower half.

Market cap
$507.8M
Ticker Nerd rank
42/ 100
Median analyst target
$56
Analysts covering
15
Revenue$0.0
Operating income−$18.4M
Net income−$16.0M
Free cash flow−$15.7M
Quarterly, 5 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.1%
1M
−29.5%
YTD
+87.3%
1Y
+130.3%
From 52W high
−50.1%
From 52W low
+153.4%
$8
$40
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

FTH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Faeth Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026
42/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
88
Momentum
72
Value
64
Size
52
Volatility
50
Quality
40
Issuance
35
Revisions
29
Growth
17

Accruals (88): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (17): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

FTH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on FTH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Jan 26Apr 26Jul 26Oct 26FTHHigh $70Median $56Low $40

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
15 Buy0 Hold0 Sell
Low $40Median $56High $70

The green dot is the last close — the median target sits +180.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
27 Oct 2026BTIGReiteratesBuy$55
16 Oct 2026William BlairInitiatesOutperform—
16 Oct 2026William BlairInitiatesOutperform—
16 Sept 2026GuggenheimInitiatesBuy$70
16 Sept 2026GuggenheimInitiatesBuy—
14 Sept 2026LUCID CAPITAL MARKETSInitiatesBuy$59
14 Sept 2026LUCID CAPITAL MARKETSInitiatesBuy—
9 Sept 2026TD CowenInitiatesBuy—
9 Sept 2026TD CowenInitiatesBuy—
21 Aug 2026NeedhamInitiatesBuy—
21 Aug 2026NeedhamInitiatesBuy$56
11 Aug 2026HC Wainwright & Co.ReiteratesBuy$60
11 Aug 2026HC Wainwright & Co.ReiteratesBuy—
4 Aug 2026Jones TradingInitiatesBuy$55
4 Aug 2026Jones TradingInitiatesBuy—
31 July 2026Raymond JamesInitiatesOutperform$56
31 July 2026Raymond JamesInitiatesOutperform—
28 July 2026OppenheimerInitiatesOutperform$60
28 July 2026OppenheimerInitiatesOutperform—
20 July 2026CitizensInitiatesMarket Outperform$51

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

FTH appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

FTH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, Faeth Therapeutics, Inc. returned +130.3% against +14.8% for the S&P 500, dividends included.

FTH vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500Jan 26Apr 26Jul 26Oct 26FTHS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

FTH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Faeth Therapeutics, Inc. (FTH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.2×

Cheaper than 84% of US stocks

Price / sales
—
Price / book
2.9×

Cheaper than 31% of US stocks

EV / EBITDA
−8.8×

Cheaper than 84% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−195.3%

Higher than 8% of US stocks

Return on assets
−20.8%

Higher than 19% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Faeth Therapeutics, Inc. (FTH) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Faeth Therapeutics, Inc. has a market value of $507.8M and an enterprise value of $321.9M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$195.5M.

  • Free cash flow in the twelve months to 30 June 2026: −$33.9M.

  • Faeth Therapeutics, Inc. spent $16.9M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 25.8M.

  • Trailing P/E: −1.2×; forward P/E: −5.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Faeth Therapeutics, Inc. employs 29 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

FTH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
FTHFaeth Therapeutics, Inc.$507.8M42
STTKShattuck Labs, Inc.$516.9M68
CAPRCapricor Therapeutics, Inc.$513.0M17
OVIDOvid Therapeutics, Inc.$511.4M63
CBIOCrescent Biopharma, Inc.$510.8M47
CTMXCytomX Therapeutics, Inc.$508.0M35
INDPIndaptus Therapeutics, Inc.$506.8M28

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Faeth Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest FTH news & analysis

Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates

Business Wire · 3 Nov 2026positive

Faeth Therapeutics reported financial results for the quarter ended September 30, 2026, and outlined recent accomplishments and 2026 milestones. The company said PIKTOR PK/PD analysis informed the dose for its Phase 2 PIK-201 trial and that PIKT received Fast Track designation.

Why it matters — The update covers Faeth’s clinical development progress and regulatory designation for its lead program, alongside quarterly financial results.

Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors

Business Wire · 27 Oct 2026positive

Faeth Therapeutics appointed Adam Schayowitz, Ph.D., MBA, to its Board of Directors. Schayowitz is Zymeworks’ Executive Vice President and Head of Research and Development, with nearly 20 years of experience in oncology drug development.

Why it matters — The appointment adds an experienced oncology drug-development executive to Faeth’s board as the company develops cancer therapies, including its lead program PIKTOR.

Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib

Business Wire · 23 Oct 2026positive

Faeth Therapeutics announced that it presented updated preclinical data on its PIKTOR program at the ESMO Congress 2026 in Madrid. The poster described PIKTOR, a combination of serabelisib and sapanisertib, with SERDs and a CDK4/6 inhibitor.

Why it matters — The presentation provides FTH watchers with an update on preclinical research involving the company’s lead program.

Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire · 22 Oct 2026neutral

Faeth Therapeutics granted three new employees options to purchase a total of 17,000 common shares. The awards were effective October 19, 2026, under the company's 2026 Inducement Plan as an inducement to employment.

Why it matters — FTH watchers may note the employee equity awards and the aggregate number of shares covered.

Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026

Business Wire · 19 Oct 2026positive

Faeth Therapeutics announced that it will present preclinical data on PIKTOR at the ESMO Congress 2026 in Madrid. The poster, scheduled for October 23, will share data intended to inform PIKTOR’s ongoing development in the FTH-PIK-101 Phase 1b/2 trial.

Why it matters — The presentation will provide an update on preclinical research supporting the development of Faeth’s lead program, PIKTOR.

FAQ

Frequently asked questions about FTH stock

What is the FTH stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Faeth Therapeutics, Inc. have a median 12-month price target of $56, with estimates ranging from $40 to $70. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is FTH stock a buy right now?

Of the 15 analysts covering Faeth Therapeutics, Inc., 15 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Faeth Therapeutics, Inc. 42 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank FTH?

As at 4 Nov 2026, Faeth Therapeutics, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (88 of 100).

Will FTH stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +180.1% from the last close, and Ticker Nerd's factor model ranks Faeth Therapeutics, Inc. 42 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the FTH stock forecast for 2030?

No analyst covering Faeth Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FTH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $70 over the next 12 months.

How has FTH stock performed over the past year?

Faeth Therapeutics, Inc. returned +130.3% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Faeth Therapeutics, Inc. do?

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cancer therapies that combine metabolic and pathway-targeted approaches.

What is the latest news on FTH?

The most recent item we track (Business Wire, 3 Nov 2026): "Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates". Faeth Therapeutics reported financial results for the quarter ended September 30, 2026, and outlined recent accomplishments and 2026 milestones. The company said PIKTOR PK/PD analysis informed the dose for its Phase 2 PIK-201 trial and that PIKT received Fast Track designation.

Company

About Faeth Therapeutics, Inc.

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cancer therapies that combine metabolic and pathway-targeted approaches. Its current work centers on PIKTOR, an investigational all-oral program built around multi-node inhibition of the PI3K/AKT/mTOR pathway for endometrial and breast cancer. The company’s platform is designed to pair therapeutic molecules with precision nutrition and related treatment strategies, reflecting its emphasis on cancer metabolism and tumor-specific vulnerabilities. Faeth Therapeutics also advances research aimed at improving outcomes for patients with solid tumors through clinically tested combinations and supportive digital tools. In today’s oncology market, the company occupies a specialized role at the intersection of biotechnology, metabolic intervention, and precision medicine.

CEO Mr. Anand Parikh Esq., J.D. · 29 employees · United States · https://www.faeththerapeutics.com